Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · regulatory

Burning Rock Biotech : OncoCompass Target CDx Kit Enters NMPA Priority Approval Procedure

10 October 2026 · By · Wire by Fusion42

Published

10 October 2026

Topic

regulatory

◆ Sectors

Medtech

◆ Geography

China

◆ Source

Read at marketscreener.com →

◆ Verified

Fusion42 · 10 October 2026 · Fusion42 review

Burning Rock Biotech's OncoCompass® Target CDx Kit has entered the National Medical Products Administration (NMPA) priority approval procedure for medical devices in China, accelerating its regulatory review process.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

Founders in medtech aiming to enter or expand in China now face a faster path to market for innovative diagnostics, making it vital to accelerate regulatory preparations for priority review pathways.

◆ Coverage

1 source · 10 Oct 2026

◆ Related on Wire

◆ Topics

Medtechregulatory-approvalmedtechchinacdx-kitnmpa-priority